Evidence map›Paper›PMID 36717151›Full record

ArticleBMJ open2023

Attitudes towards participating in research involving digital pill systems to measure oral HIV pre-exposure chemoprophylaxis: a cross-sectional study among men who have sex with men with substance use in the USA.

Peter Chai, Dikha De, Hannah Albrechta, Georgia R Goodman, Koki Takabatake, Amy Ben-Arieh, Jasper S Lee, Tiffany R Glynn, Kenneth Mayer, Conall O'Cleirigh and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Leveraging virtual reality to improve medication adherence among marginalized populations with high-risk chronic health conditions: Proof-of-concept protocol, considerations, and next steps.Proceedings of the ... Annual Hawaii International Conference on System Sciences. Annual Hawaii International Conference on System Sciences · 2025
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Peter ChaiDepartment of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA pchai@bwh.harvard.edu.ORCID 0000-0003-0955-4117
Dikha DeFenway Institute, Boston, Massachusetts, USA.
Hannah AlbrechtaFenway Institute, Boston, Massachusetts, USA.
Georgia R GoodmanDepartment of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Koki TakabatakeFenway Institute, Boston, Massachusetts, USA.
Amy Ben-AriehFenway Institute, Boston, Massachusetts, USA.ORCID 0000-0002-7170-6014
Jasper S LeeFenway Institute, Boston, Massachusetts, USA.
Tiffany R GlynnFenway Institute, Boston, Massachusetts, USA.
Kenneth MayerFenway Institute, Boston, Massachusetts, USA.
Conall O'CleirighFenway Institute, Boston, Massachusetts, USA.
Celia FisherCenter for Ethics Education, Fordham University, New York, New York, USA.
Massachusetts General Hospital · USBoston University · USBrigham and Women's Hospital · USFenway Health · USBeth Israel Deaconess Medical Center · USFordham University · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
PROGRAM FOR AIDS CLINICAL RESEARCH TRAINING (PACRT)T32AI007433 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MARK J SIEDNER · 1992 to 2026
$11.4M
Training Program in HIV Prevention Research EthicsR25DA031608 · NIDA · FORDHAM UNIVERSITY · PI FISHER, CELIA B · 2011 to 2025
$4.9M
Smart Steps: A context-aware adherence intervention to improve PrEP adherence among men who have sex with men (MSM) with substance use disorderDP2DA056107 · NIDA · BRIGHAM AND WOMEN'S HOSPITAL · PI CHAI, PETER R · 2022 to 2022
$2.7M
Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance UsersK23DA044874 · NIDA · BRIGHAM AND WOMEN'S HOSPITAL · PI CHAI, PETER R · 2018 to 2022
$1.0M
NIAID NIH HHS P30 AI060354NIAID NIH HHS T32 AI007433NIDA NIH HHS DP2 DA056107NIDA NIH HHS K23 DA044874NIDA NIH HHS R25 DA031608
6 · The paper itself

Abstract

objectivesThis quantitative survey sought to understand, among men who have sex with men (MSM) with potentially problematic substance use, the attitudes towards participation in research involving digital pill systems (DPS) for HIV pre-exposure prophylaxis (PrEP) adherence measurement, and the barriers and facilitators to research participation.

designOne-time, cross-sectional, online sampling-based survey.

settingUS social networking app predominantly focused on MSM.

participantsMSM without HIV who reported current use of oral PrEP, potentially problematic substance use and sexual activity in the past 3 months. A total of 157 participants were eligible, passed validity checks and enrolled. OUTCOME MEASURES: Perceptions of DPS usefulness, accuracy and usability (System Usability Scale (SUS)); willingness and motivations to participate in DPS research; preferences for access to and feedback on DPS adherence data; data sharing considerations; and medical mistrust (Group-Based Medical Mistrust Scale (GBMMS)).

resultsMost of the sample (N=157) was white (n=119, 75.8%), gay (n=124, 79.0%) and cisgender (n=150, 95.5%). The median age was 33 years (IQR: 14). The mean GBMMS score was 13.5 (SD=5.2), and the median SUS score was 70 (IQR: 27.5). In the past 3 months, 36.3% (n=57) reported frequent use of substances before or during sex, and 62.4% (n=98) engaged in condomless sex. While most were adherent to PrEP, approximately 34.4% (n=54) expressed significant worry about daily adherence. Participants wished to monitor their PrEP adherence daily (n=66, 42.0%) and 52% (n=82) were very willing to participate in DPS-based research. The majority were minimally concerned about sharing DPS-detected adherence data with research teams (n=126, 80.3%), and were extremely willing to share these data with healthcare providers (n=109, 69.4%).

conclusionsIn this sample, MSM without HIV who use substances reported willingness to use DPS to measure PrEP adherence in a research context, and identified benefits to accessing real-time, DPS-detected adherence data.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisSexual and Gender MinoritiesSubstance-Related DisordersAdultCross-Sectional StudiesHealth Knowledge, Attitudes, PracticeHomosexuality, MaleHumansMaleSexual BehaviorTrustAnti-HIV AgentsHealth informaticsHIV & AIDSPREVENTIVE MEDICINESubstance misuse

Identifiers

PMID36717151
PMCPMC9887701
OpenAlexW4318671913

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.